ABSTRACT

Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is a significant health issue worldwide and can accelerate liver damage when they occur together. This study presents the treatment process of a 52-year-old female patient with HCV and HBV co-infection. The patient was initiated on direct-acting antiviral therapy (glecaprevir and pibrentasvir) for HCV infection and entecavir for HBV reactivation. As a result of treatment, both HCV-RNA and HBV-DNA became negative, and a sustained virologic response was achieved for HCV. Our study highlights the effectiveness of modern treatment approaches for patients with HBV and HCV co-infection.